Cambrex Invests $30 Million in Milan R&D Expansion

The new facility, slated for completion in the second half of 2027, represents a significant upgrade to the infrastructure at the Cambrex Profarmico Milano site. Beyond the immediate construction, the company has secured additional land adjacent to the property, creating a buffer for future operational growth. This strategic move follows the site's 80th anniversary, an occasion recently commemorated by the local staff and leadership.

Claudio Russolo, Chief Operating Officer at Cambrex, described the investment as a commitment to both technological advancement and the site’s professional heritage. By integrating new R&D capacity, the company intends to streamline its support for the pharmaceutical industry’s evolving requirements in small molecule development. The project serves as a cornerstone of the firm's broader efforts to modernize its European manufacturing footprint.